The recent $12 billion acquisition of Kite Pharma, Inc. by big-pharma giant, Gilead Sciences has biotech investors hungry for the next big buyout target. This has begged the question, “Does this one biotech stock have what it takes to be a billion dollar opportunity?”
CLICK HERE TO ACCESS THIS FULL REPORT
MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com